Compare AbCellera Biologics Inc (ABCL) vs Campbell Soup Co. (CPB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Campbell Soup Co. — how do they compare? AbCellera Biologics Inc trades at $7.18 (market cap $2.35B), while Campbell Soup Co. trades at $22.22 (market cap $6.83B). The key difference: Campbell Soup Co. is far larger — about 2.9× AbCellera Biologics Inc's market cap, and Campbell Soup Co. pays a 6.81% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | CPB | |
|---|---|---|
Market Cap | $2.35B | $6.83B |
Sector | Health | Consumer Staples |
52-Week High | $8.12 | $34.03 |
52-Week Low | $2.78 | $20.00 |
Enterprise Value | $1.99B | $13.44B |
Dividend Yield | — | 6.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Campbell's (CPB) trades at $22.90, down 1.8% today, with mixed technical signals showing bullish moving averages but neutral oscillators. The stock offers a 7% dividend yield but faces margin pressures with net income margin at 6.12%. Recent Q1 2026 earnings beat expectations at $0.50 EPS, though sales declined 4% year-over-year. The company is implementing cost cuts and portfolio simplification while expanding through partnerships like the new gluten-free soup with Banza.
CPB presents a value opportunity with low P/E of 11.11 and P/S of 0.68, but faces structural challenges including margin deterioration and competitive pressures. Analyst consensus leans cautious with 55% hold ratings and $19.75 price target below current levels. The high dividend yield provides income support, but investors should monitor execution of cost-saving initiatives and consumer response to new product innovations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →
